What Waystar (WAY) Said on Its Q3 Earnings Call
Waystar (WAY) reported Q3 bookings for Iodine exceeded year-to-date plans by 74%, with $15M in Q3 bookings. The company launched an autonomous claim-resubmission feature, estimating it could resubmit up to $5B in rejected claims annually. Waystar lowered its full-year revenue forecast to $1.277B-$1.287B but raised adjusted EBITDA guidance to $543M-$549M. The company cited timing pressures for the revenue outlook adjustment.
How this was made
The 30-second read
Why it matters
The revenue guidance cut signals slower growth, while the EBITDA raise and buyback indicate confidence in profitability, creating a mixed outlook for traders.
Market read
First‑report earnings and guidance update for WAY, driving potential price movement.
What to watch
The $21M buyback and strong AI product bookings may cushion the revenue shortfall.
Background
Waystar Holding Corp. (NASDAQ:WAY) disclosed its Q3 earnings call details, including product performance, guidance updates, and capital allocation.
Ticker impact
Waystar reported Q3 bookings, lowered full-year revenue guidance to $1.277‑$1.287B and raised adjusted EBITDA guidance, plus a $21M stock repurchase.
likely pressure as the market prices in the lower revenue outlook
Revenue guidance cut and slower growth in the Iodine segment outweigh the modest EBITDA raise and buyback, prompting traders to consider short positions or reduce exposure.
Market effects
Healthcare‑tech firms may face scrutiny on revenue guidance amid AI‑driven product rollouts.
U.S. market sentiment could dip slightly in the health‑tech niche.
Limited to investors tracking U.S. health‑tech equities.
Counterpoint
The raised EBITDA guidance and ongoing AI investments could support a longer‑term upside if execution improves.
Key entities
- CompanyWaystar Holding Corp.
U.S. listed healthcare‑technology firm.
- ExecutiveAmit Khanna
New chief product and technology officer.
